Loading...
•
Dec 31, 2023
ACADIA Q4 2023 Earnings Report
Acadia reported Q4 2023 financial results, achieving revenue growth driven by DAYBUE and NUPLAZID sales, and advancing its pipeline with Phase 3 and Phase 2 trials.
Key Takeaways
Acadia Pharmaceuticals reported a transformational year in 2023, achieving 40% revenue growth driven by the launch of DAYBUE and growth in the NUPLAZID franchise. In the fourth quarter, the company advanced its pipeline with the initiation of Phase 3 and Phase 2 trials and reported net income of $45.8 million.
Total net product sales of $726.4 million for 2023, reflecting 40% revenue growth.
DAYBUE net product sales of $87.1 million for the fourth quarter and $177.2 million for the full year 2023.
NUPLAZID net product sales of $143.9 million for the fourth quarter and $549.2 million for the full year 2023.
Initiated a Phase 3 trial of ACP-101 in Prader-Willi syndrome and a Phase 2/Phase 3 program for ACP-204 in Alzheimer’s disease psychosis in Q4 2023.
Revenue by Segment
Forward Guidance
Acadia provided full year 2024 financial guidance.
Positive Outlook
- DAYBUE net product sales in the range of $370 to $420 million.
- NUPLAZID net product sales in the range of $560 to $590 million.
- GAAP R&D expense in the range of $305 to $325 million.
- GAAP SG&A expense in the range of $455 to $480 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...